



FACULTY EXPECTATIONS

PARTICIPATION BY FACULTY MEMBER AND MEMBERS OF THEIR LABORATORY

1. Your insight, knowledge and reagents are unique and extremely valuable to the success and novelty of your project. We expect you to share this information openly to enable rapid implementation for success of your program.
2. If selected, you will present your application to the External Advisory Board in a 12-minute seminar, followed by questions, for 20 minutes total. There will be a method for presenting remotely using Zoom if you are not available in person.
3. We will need your help in transferring knowledge and reagents relevant to the project from your lab to the YCMD. While you will not be compensated for reagents you may have already produced (e.g. proteins, cell lines, etc.) to support your PITCH program, you will **not pay** for any YCMD services or assay/readout reagents to support work for your PITCH project (except for *in vivo* experiments- a lean budget for animal studies has been included in the PITCH project but those funds may be insufficient, depending on the animal model needed for a project). In addition, the costs and labor for other reagents *generated in your lab* during the PITCH project will not be compensated.
4. Should you want additional studies performed that are related to the PITCH project, but outside of the purview of the project, costs will be discussed with you and if you agree, you will be charged the prevailing YCMD rates.
5. You will be provided with periodic project updates.
6. Should your project complete the PITCH program, your participation, passion and commitment will be critical factors in the decision of investment groups to invest in further development.

PROGRAM ADMINISTRATION

1. PITCH is administered and implemented by experienced scientists and administrators with applicable standards for professional behavior and communication. Members of your laboratory will not be directly involved in hands-on assay activities for the PITCH project but may be needed to provide additional counterscreens and/or reagents to characterize fully hit compounds identified in the initial screen.
2. Several approaches both for assay design and for the mechanics of screening might be available to address your project, and they might have redundant and complementary capabilities. You should discuss your project with YCMD to understand the resources that are available and to select the most appropriate approach prior to submitting your application.

ROLE OF THE EXECUTIVE COMMITTEE AND BOARD MEMBERS IN PITCH

1. Projects will be evaluated and selected for PITCH by the External Advisory Board (EAB) based on scientific merit, feasibility, and commercial potential. EAB members will also evaluate projects after the assay development and screening phase – only selected projects will proceed to the next medicinal chemistry phase. PITCH administrators and personnel will not decide which projects are selected or advanced through the PITCH program.
2. Board members have signed a Confidentiality and Non-Disclosure Agreement prior to participation as a member of the Executive Committee or External Advisory Board.
3. Board members have signed a Conflict of Interest policy and will identify any conflicts which could bias their decision making for each project. They will recuse themselves from voting on projects for which a conflict is identified.
4. You will not receive written feedback about the decision to move your project forward or to hold your project.

INTELLECTUAL PROPERTY AND ROYALTY DISTRIBUTION

1. The intellectual property developed during PITCH is owned by your university. However, during the project, PITCH scientists may become inventors as determined by patent law. In those cases, they will participate in any future revenue sharing per the policies in place at the university from which the project originated.
2. You must engage the technology transfer group at your host institution prior to any publications to ensure that the intellectual property remains intact for engagement of investment groups. Publications must acknowledge the financial support of PITCH and, when appropriate, include the PITCH scientists who have contributed to the findings in the submitted manuscript.
3. A PITCH project cannot be funded by any other group or funding agency if that would result in granting IP rights to a third party (e.g., sponsored research from a pharmaceutical company or private foundation). However, you can submit the project for alternative funding while it is being actively executed by PITCH to agencies that assign IP rights to your home university (e.g., federal funding such as NIH, DoD).
4. Revenue resulting from royalties, milestones, licensing, or other capital-generating events which participated in PITCH will be distributed according to Yale policies regarding faculty inventor revenue sharing and to the allocations established in the royalty sharing agreement between Yale and Connecticut Innovations. The basis of the agreement is to incentivize all groups as stakeholders in the success of the program.

FACULTY NAME AND INSTITUTION

SIGNATURE AND DATE
